Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation

Release Date:
Monday, October 8, 2018 6:16 pm EDT

Terms:

Dateline City:
CAMBRIDGE, MA

Contacts:
Sanofi Media Relations Contact Ashleigh Koss Tel.: +1 (908) 981-8745 Ashleigh.Koss@sanofi.com
Regeneron Media Relations Contact Daren Kwok Tel.: +1 (914) 847-1328 Daren.Kwok@regeneron.com
Regeneron Investor Relations Contact Manisha Narasimhan, Ph.D. Tel.: +1 (914) 847-5126 Manisha.Narasimhan@regeneron.com

* ESMO data demonstrate breadth of joint Sanofi and Regeneron immuno-oncology development program

* ESMO presentations follow the recent U.S. FDA approval of Libtayo for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will present a diverse set of data from their joint clinical program investigating Libtayo® (cemiplimab-rwlc) at the ESMO 2018 Congress (European Society for Medical Oncology) from October 19 to 23 in Munich, Germany. These data span six different tumor types, including non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC) and basal cell carcinoma (BCC). Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1).

“Following the U.S. FDA approval of Libtayo in advanced CSCC, we remain focused on pursuing science that has the potential to change treatment paradigms in oncology,” said Israel Lowy, M.D., Ph.D., Vice President of Global Clinical Development and Head of Translational Science and Clinical Oncology, Regeneron. “At ESMO, we look forward to sharing new data that support our rationale for pursuing registrational trials of Libtayo in lung, cervical and skin cancers.”

All six of the abstracts accepted at ESMO focus on ongoing Libtayo clinical trials.

“Three years ago, Sanofi began its immuno-oncology collaboration with Regeneron with the shared vision to address significant unmet needs across various cancer types,” said Joanne Lager, M.D., Head of Oncology Development, Sanofi. “This year’s data being presented at ESMO are a testament to our commitment to patients and the potential to make our vision a reality.”

Among the joint Sanofi and Regeneron presentations are new clinical data from a Phase 1 expansion cohort investigating Libtayo in combination with radiotherapy in advanced NSCLC as well as longer-term follow-up data from the advanced CSCC expansion cohorts in the Phase 1 trial. Additional abstracts will feature initial data from Phase 1 expansion cohorts investigating Libtayo in cervical cancer, HCC and HNSCC, alongside a trial-in-progress update on the potentially pivotal Phase 2 trial in BCC.

Sanofi and Regeneron joint presentations at ESMO include:

- Cemiplimab, a human PD-1 monoclonal antibody, in patients with recurrent or metastatic cervical cancer: interim data from phase 1 cohorts
  Danny Rischin Oct 20/12:30-13:30/958P

- Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy in advanced non-small cell lung cancer (NSCLC): Results from a Phase 1 expansion cohort (EC 2)
  Victor Moreno, Oct 20/12:30-13:30/1162P

- Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally
Getting medical treatment right away may help keep these problems from becoming more serious.

**IMPORTANT SAFETY INFORMATION AND INDICATION FOR U.S. PATIENTS**

What is the most important information I should know about Libtayo?

Libtayo is a medicine that may treat a type of skin cancer by working with your immune system. Libtayo can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes be severe and life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any symptoms of the following problems or these symptoms get worse:

- **Lung problems (pneumonitis).** Signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath, and chest pain.
- **Intestinal problems (colitis) that can lead to tears or holes in your intestine.** Signs and symptoms of colitis may include diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or that have blood or mucus; and severe stomach-area (abdomen) pain or tenderness.
- **Liver problems (hepatitis).** Signs and symptoms of hepatitis may include yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), drowsiness, dark urine (tea colored), bleeding or bruising more easily than normal, and feeling less hungry than usual.
- **Hormone gland problems** (especially the adrenal glands, pituitary, thyroid and pancreas). Signs and symptoms that your hormone glands are not working properly may include headaches that will not go away or unusual headaches, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, dizziness or fainting, feeling more hungry or thirsty than usual, hair loss, feeling cold, constipation, deeper voice, very low blood pressure, urinating more often than usual, nausea or vomiting, stomach-area (abdomen) pain, and changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness.
- **Kidney problems,** including nephritis and kidney failure. Signs of these problems may include decrease in your amount of urine, blood in your urine, swelling in your ankles, and loss of appetite.
- **Skin problems.** Signs of these problems may include rash, itching, skin blistering, and painful sores or ulcers in the mouth, nose, throat, or genital area.
- **Problems in other organs.** Signs of these problems may include headache, tiredness or weakness, sleepiness, changes in heartbeat (such as beating fast, seeming to skip a beat, or a pounding sensation), confusion, fever, muscle weakness, balance problems, nausea, vomiting, stiff neck, memory problems, seizures (encephalitis), swollen lymph nodes, rash or tender lumps on skin, cough, shortness of breath, vision changes, or eye pain (sarcoidosis), seeing or hearing things that are not there (hallucinations), severe muscle weakness, low red blood cells (anemia), bruises on the skin or bleeding, and changes in eyesight.
- **Rejection of a transplanted organ.** Your doctor should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.
- **Infusion (IV) reactions that can sometimes be severe and life-threatening.** Signs of these problems may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, fever, feeling of passing out, back or neck pain, and facial swelling.
Your healthcare provider will check you for these problems during your treatment with Libtayo. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may delay or completely stop treatment if you have severe side effects.

Before you receive Libtayo, tell your healthcare provider about all your medical conditions, including if you:

- have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus;
- have had an organ transplant;
- have lung or breathing problems;
- have liver or kidney problems;
- have diabetes;
- are pregnant or plan to become pregnant; Libtayo can harm your unborn baby

Females who are able to become pregnant:

- Your healthcare provider will give you a pregnancy test before you start treatment.
- You should use an effective method of birth control during your treatment and for at least 4 months after your last dose of Libtayo. Talk with your healthcare provider about birth control methods that you can use during this time.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Libtayo.
  - are breastfeeding or plan to breastfeed. It is not known if Libtayo passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of Libtayo.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of Libtayo include tiredness, rash, and diarrhea. These are not all the possible side effects of Libtayo. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals and Sanofi at 1-877-542-8296.

Please see accompanying full Prescribing Information, including Medication Guide.

What is Libtayo?

Libtayo is a prescription medicine used to treat people with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation.

It is not known if Libtayo is safe and effective in children.

About Regeneron Pharmaceuticals, Inc

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to
approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or commercial potential of such product candidates,
the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and
commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending
or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates,
volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average
number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi
does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements and Use of Digital Media

This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the
future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may
differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,”
“seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking
statements, although not all forward-looking statements contain these identifying words. These statements concern, and
these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of
Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without
limitation Libtayo® (cemiplimab-rwlc) for the treatment of patients with cutaneous squamous cell carcinoma, non-small cell
lung cancer (“NSCLC”), cervical cancer, hepatocellular carcinoma (“HCC”), and head and neck squamous cell carcinoma (“HNSCC”),
basal cell carcinoma (“BCC”), and other potential indications; the likelihood and timing of achieving any of Regeneron's
anticipated clinical development milestones; unforeseen safety issues resulting from the administration of products and
product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's
product candidates (such as Libtayo) in clinical trials; the likelihood and timing of possible regulatory approval and commercial
launch of Regeneron's late-stage product candidates and new indications for marketed products, including without limitation
Libtayo for the treatment of NSCLC, cervical cancer, HCC, HNSCC, BCC, and other potential indications; the extent to which
the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in
other studies and lead to therapeutic applications; ongoing regulatory obligations and oversight impacting Regeneron's
marketed products (such as Libtayo), research and clinical programs, and business, including those relating to patient
privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's
ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product
candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and
commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage
supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third
parties to perform filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's products and
product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid;
unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of
its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential
for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical
Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further
product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto,
including without limitation the patent litigation proceedings relating to EYLEA® (aflibercept) Injection, Dupixent®
(dupilumab) Injection, Praluent® (alirocumab) Injection, the ultimate outcome of any such litigation proceedings, and the
impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more
complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and
Exchange Commission, including its Form 10-K for the fiscal year ended December 31, 2017 and its Form 10-Q for the
quarterly period ended June 30, 2018. Any forward-looking statements are made based on management’s current beliefs and
judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does
not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information,
future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the
Company, including information that may be deemed material to investors. Financial and other information about Regeneron
is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com)
and its Twitter feed (http://twitter.com/regeneron).


Language:
English

tumor-types-u